Advances in Acute Myeloid Leukemia (AML) Management: Focus on Secondary AML and Older Patients with AML

Advances in the molecular understanding of acute myeloid leukemia (AML) has enhanced risk stratification and optimized therapeutic strategies. However, there is still a need for improved therapeutic strategies to combat AML disease progression, especially in older patients and patients with secondary AML. Some novel treatment options are associated with improved clinical outcomes and fewer side effects than the conventional standard regimens. In most cases, there are unique adverse effects that require specialized supportive care. Clinicians need to be informed about these therapeutic advances and necessary supportive care precautions to aid in their efficacious and safe incorporation into clinical practice for the appropriate AML patient subpopulations. 

This information was originally presented at the NCCN 2020 Virtual Congress: Hematologic Malignancies™  held on October 9-10, 2020.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Describe current treatment strategies for acute myeloid leukemia (AML).
  • Identify emerging management strategies for secondary AML and older patients with AML.
  • Compare and contrast unique supportive care considerations associated with newer AML therapies.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Bayer Healthcare Pharmaceuticals
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Jazz Pharmaceuticals, Inc.
  • Novartis
  • Pharmacyclics LLC, an Abbvie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.
  • Seattle Genetics, Inc. 
  • Takeda

This activity is supported by independent educational grants from:

  • Abbvie
  • Astellas
  • Incyte

This activity is supported by an independent medical education grant from Bristol Myers Squibb.

Course summary
Available credit: 
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Course opens: 
10/30/2020
Course expires: 
10/30/2021
Cost:
$0.00

Daniel A. Pollyea, MD, MS
University of Colorado Cancer Center

 

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions 

NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures

The faculty listed below discloses the following relevant financial relationships:

Daniel A. Pollyea, MD, MS
AbbVie, Inc.: Scientific Advisor
Amgen Inc.: Scientific Advisor
Bristol-Myers Squibb Company: Scientific Advisor
Celgene Corporation: Scientific Advisor
Genentech, Inc.: Scientific Advisor
GlycoMimetics, Inc. Scientific Advisor
Karyopharm Therapeutics: Scientific Advisor
Kiadis Pharma: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Syndax Pharmaceuticals Inc.: Scientific Advisor
Syros Pharmaceuticals: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Leadership listed below discloses no relevant financial relationships: 
Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR 

The NCCN Leadership listed below discloses the following relevant financial relationships: 
Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Liz Hollinger, RN, BSN; Ndiya Ogba, PhD

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.50 contact hour.

Pharmacists
NCCN designates this application-based continuing education activity for 0.50 contact hour (0.05 CEUs) of continuing education credit. UAN: JA4008196-0000-20-108-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: